Insilico Medicine said first-in-human Phase 1 data for ISM6331 have been accepted for a Rapid Oral presentation at the 2026 ESMO Congress. ISM6331 is described as an AI-designed pan-TEAD inhibitor, targeting the Hippo signaling pathway implicated in aggressive solid tumors. The company’s disclosure frames ISM6331 as a small-molecule strategy aimed at modulating Hippo pathway signaling through TEAD inhibition, with the presentation offering the next public view of early safety and pharmacodynamic signals. Insilico said it is seeking to move beyond traditional discovery workflows using AI to propose tractable targets and refine candidates for translation. At ESMO, the Rapid Oral format typically emphasizes tightly curated datasets, often including early exposure and biomarker readouts that help investors and clinicians assess whether the mechanism supports further clinical development. The acceptance also signals continuing confidence in AI-designed targets making it into clinical communication pipelines as oncology companies compete for next-generation pathway modulators.